Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H4I8
UPID:
SEHL2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H4I8; B1AHE9; B1AHF0; Q0VDJ1; Q5H973; Q9BR29; Q9BR30; Q9Y3I9
Background:
Serine hydrolase-like protein 2, encoded by the gene with accession number Q9H4I8, is classified as a probable serine hydrolase. This protein is implicated in processes that may be pivotal to muscle cell hypertrophy, suggesting a role in muscle growth and development.
Therapeutic significance:
Understanding the role of Serine hydrolase-like protein 2 could open doors to potential therapeutic strategies. Its involvement in muscle hypertrophy highlights its potential as a target for conditions related to muscle growth and regeneration.